Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2017.8262 mmr-17-02-3035 Articles Betulinic acid-induced expression of nicotinamide adenine dinucleotide phosphate-diaphorase in the immune organs of mice: A possible role of nitric oxide in immunomodulation PangKai Le 1 * VijayaraghavanKavitha 2 SayedBadr Al 3 SeyedMohamed Ali 3 * Faculty of Pharmacy, Universiti, Kebangsaan Malaysia (UKM), The National University of Malaysia, Kuala Lumpur 50300, Malaysia Agni College of Technology, Thalambur, Chennai 600 130, India Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi Arabia Correspondence to: Professor Mohamed Ali Seyed, Faculty of Medicine, University of Tabuk, 1 Tabuk Duba Main Road, Tabuk 71491, Saudi Arabia, E-mail: sdmdali.ali@gmail.com

Contributed equally

 022018 12122017 17 2 3035 3041 05072017 30102017 Copyright: © Pang et al. 2018 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The aim of the present study was to investigate the effects of betulinic acid (BetA) on the expression and distribution pattern of nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d), an indirect indicator of nitric oxide (NO) synthase in the thymus and spleen of mice. Mice were randomly assigned to four main groups (n=48 per group): Experimental group (BetA), positive control group (goniothalamin), vehicle control group (dimethyl sulfoxide) and control group (without vehicle). Each group was further divided into three equal subgroups according to the treatment length (4, 8 and 12 days). BetA treatment induced the expression of NADPH-d activity in the thymus and spleen without any significant changes in the morphology of the organs. Furthermore, the expression pattern of NADPH-d in BetA-treated animals was significantly increased compared with that in the control animals. NADPH-d expression in the thymus and spleen suggests that NO signaling may be a potential mechanism underlying the BetA-induced immunomodulation in these organs. These findings are of direct clinical relevance and may contribute to the further development of BetA as a therapeutic drug.

 nicotinamide adenine dinucleotide phosphate diaphorase nitric oxide betulinic acid mice thymus spleen Introduction

Numerous diseases, including cancer require modulation in the immune system for disease management and care (1). Under the circumstance of weakened immune responsiveness, the host protection machinery has to be activated to provide an alternative to conventional chemotherapy (2). Potential immunomodulatory agents (3,4) have been identified based on the observed therapeutic effects of phytochemicals isolated from various plants (5–7), and segregates of microorganisms and mammalian proteins, including immune mediators and certain synthetic chemicals (8).

The triterpene alcohol, betulin and its equivalent carboxylic acid, betulinic acid (BetA; Fig. 1) are isolated from betula birch bark (9), which has been used for various medicinal purposes in many countries (10). BetA is a pentacyclic lupane-type triterpenoid of which a wide range of biological properties have been shown against cancer, inflammation, malaria, and helmintic and viral activities (11–14). Among these, the anticancer and cytotoxic activities of BetA have received significant attention (15,16). Selective cytotoxicity has been demonstrated in multiple tumor cell lines (15–19) without effect in normal cells, including dermal fibroblasts and peripheral blood lymphocytes (20–22). Furthermore, no systemic toxic effects have been observed in rodents (23). However, BetA is considered to be a weak antineoplastic agent, as it is required at micromolar concentrations to inhibit cell proliferation in vitro, and even higher doses are required (250 mg/kg body weight) to control melanoma growth in athymic mice (24).

Despite a lack of toxicity, the poor potency of BetA hinders its clinical development. Mullauer et al (23) cautioned that existing in vivo data are insufficient to support that BetA does not cause an effect on healthy cells. Furthermore, in contrast to previous findings, a recent study by Heiss et al (24) reported that 10 µM BetA induces changes in normal cellular metabolism. The study by Heiss et al (24) raised concerns regarding the clinical application of BetA and prompted us to investigate whether BetA may cause any major effects on healthy cells in the immune organs of mice.

Nitric oxide (NO) is a free radical and ubiquitous signaling molecule (25,26) present in immune and endocrine tissues, among others (27–29) and a well-known mediator in numerous therapeutic and immuomodulatory functions, indicating a regulatory function of NO in primary and secondary immune organs. There are three isoforms of NO synthases (NOSs), which are neuronal (nNOS), inducible (iNOS) and endothelial (eNOS), and they are responsible for the synthesis of NO from the amino acid, l-arginine (30). Previous studies have demonstrated that all three isoforms express enzymatic activity of NADPH-d (31,32), and indicated the expression pattern of NADPH-d is an indirect indication of the presence of NOS and NO (30,33). Therefore NADPH-d activity has been used as a marker for NOS.

Therefore, the current study was performed to determine whether 10 µM BetA modulates NO production or induces changes in healthy spleen and thymus cells in mice, and to investigate the possible functions of BetA in these organs. A histochemical analysis of NADPH-d, a marker for NOS, was also performed (34).

 Materials and methods <sec> <title>Animals and reagents

Animal experiments were conducted in accordance with the National University of Malaysia (UKM; Kuala Lumpur, Malaysia) animal ethics guidelines and regulations laid out by the Institutional Animal Ethics Committee (UKMAEC; FF/2016/ALI/20-MAY/685-JUNE-2016). Six-week-old, female BALB/c mice procured from the institutional animal holding facility (n=196), were maintained (2–3 animals/cage) under pathogen-free conditions and a 12-h light/dark cycle, with access to commercial pellets and distilled water. BetA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) served as a test drug, goniothalamin (GTN; provided by Dr Ibrahim Jantan, Faculty of Pharmacy, UKM) served as a positive control drug, and dimethyl sulfoxide (DMSO; Merck KGaA) served as a vehicle.

 Animal treatment and sample collection

Animals were randomly divided into four main groups as follows: Experimental group (10 µM BetA; n=48), a positive control group (50 µM GTN; n=48), a negative control group (0.05% DMSO; n=48) and a normal standard control group (n=48). Each main group of animals was further divided into three equal subgroups (n=6 per group) corresponding to the treatment period (4, 8 and 12 days). Chloral hydrate (10%; i.p.) was administered to anesthetize the animals, subsequently animals were fixed using 4% paraformaldehyde and a transcardiac perfusion method described by Syed et al (27). The fixed tissue blocks were maintained in the same fixative solution for a further 6 h as post fixation, followed by rinsing in 0.1 M phosphate buffer (PB) and cryoprotection in 30% sucrose. Finally, 10 µm frozen sections were sliced (Leica SM2010 Sliding microtome; Leica Microsystems GmbH, Wetzlar, Germany). Three series of sliced sections were collected on a glass slide and stained for NADPH-d.

 Histochemistry of NADPH-d and analysis of tissue morphology

Frozen tissue sections were maintained at room temperature for 30 min, washed twice in PB, followed by staining for NADPH-d with the addition of substrate β-NADPH [Malaysia Sigma-Aldrich (M) Sdn. Bhd, Kuala Lumpur, Malaysia] and nitroblue tetrazolium, a salt that yields an insoluble blue formazan precipitate visible under a light microscope (27). In the case of NADPH-d histochemistry controls, sections were incubated at room temperature for 45 min in a β-NADPH-free medium. The intensity of the reaction in the thymus and spleen was determined by measurement of optical density (OD; 0–260 nm), using Olympus cellSens (Olympus Soft Imaging Solutions GmbH, Münster, Germany) software version 1.6, and was graphically represented. From each sample, three to four slides were subjected to the staining procedure and multiple areas were evaluated randomly using a light microscope. The cross-sectional morphology of the tissues was observed using an Olympus BX41TF microscope (Olympus Corp., Tokyo, Japan). Images of the sections were captured using an Olympus UC30, with Olympus cellSens software version 1.6. All measurements were performed in duplicate or triplicate and repeated at least three times.

 Statistical analysis

Statistical assessment of the intensity data was performed using one-way ANOVA followed by Bonferroni multiple comparison's tests (GraphPad Prism version 4.0; GraphPad Software, In., La Jolla, CA, USA). All numerical data are expressed as the mean ± standard error of the mean and P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>NADPH-d expression in the thymus

Although the control group (DMSO-treated vehicle) received no drug treatment, weak or faint NADPH-d staining was observed in the cortex and medulla region of the thymus (Fig. 2A-C), whereas in the positive-control group (GTN), the capsule and cortex region demonstrated moderate NADPH-d expression 4 days after the GTN injection, which continuously increased at the eighth and twelfth day of treatment (Fig. 2D-F). This indicates that GTN induces time-dependent expression of NADPH-d in the thymus. However, the NADPH-d distribution was initially similar to that in the control group after day 4, and subsequently the distribution spread to the whole lobule on the eighth and twelfth day of treatment.

Similarly, a gradual increase of NADPH-d distribution (P<0.001) was observed in the BetA treatment group and its activity increased along with longer BetA exposure (Fig. 2G-I). However, the thymus displayed only slight to moderate NADPH-d staining after 4 days (Fig. 2G), 8 days (Fig. 2H) and 12 days of BetA treatment (Fig. 2I), in the cortex and the medullary region. The interlobular septum extends from the capsule into the thymus, subdividing the thymus into interconnecting lobules, which are of varying size and orientation. The expression pattern of NADPH-d spread to a wider area at the medullary region across the septum 8 days after BetA treatment, demonstrating higher NADPH-d activity. As the septum is the site where blood vasculatures in the thymus are oriented, staining in this region (Fig. 2C and G) supports that NO has a role in vascular physiology. The graph (Fig. 2J) demonstrates the intensity (OD) per staining area (cm2) of the thymus tissue sections after 4, 8 and 12 days of treatment. Increased NADPH-d expression indicates that the effect of BetA on the thymus depends on exposure time.

 NADPH-d expression in the spleen

Compared with that in the control group (Fig. 3A-C), the spleen of the GTN (Fig. 3D-F) and BetA groups (Fig. 3G-I) demonstrated a particularly strong NADPH-d reaction, with increased expression levels in the cortex and medullary regions (Fig. 3D-I), as well as in the vasculature (Fig. 3C, F and I), which increased with longer exposure times. The spleen is enclosed by a fibro elastic outer connective tissue, the capsule, and composed of white and red pulp, forming two functionally and morphologically different units. The NADPH-d staining (brown precipitate) was more widely present in the red pulp than in the white pulp area. The red pulp region is comprised of various cells, including sinusoids (35). The graph (Fig. 3J) demonstrates the intensity (OD) per staining area (cm2) of the spleen tissue sections after 4, 8 and 12 days of treatment

 Morphological changes

No phenotypical appearance or significant morphological changes were observed in either the GTN- or the BetA-treated thymus and spleen.

 Discussion

The present study demonstrated positive NADPH-d staining in the thymus and in the spleen of non-immunized GTN and BetA-treated mice. However, its expression and distribution pattern varied with these agents throughout the treatment period. Although no morphological or phenotypical changes were evident in these organs, the NADPH-d activity was more prominent in the spleen than in the thymus. The red pulp region of the spleen strongly expressed NADPH-d, whereas only a moderate reactivity was observed in the white pulp region. Although NADPH-d expression was detected after 4 days, a significant increase in expression was observed after 8 days of BetA treatment, indicating the contribution of NADPH-d in spleen NO generation during the entire treatment period. Similarly, a steady increase in NADPH-d activity in the thymus beginning from day 4 may specify an interactive outcome of NO on the thymus vascular and medulla regions, which may be involved in immune modulation (33,36–37). Although the function of NO in the thymus and spleen has not been demonstrated, the findings of the current study indicate that there is an association between the immunological effects induced by BetA. The major effect of BetA-induced NO appears to be involved in maintenance of the immune system (38–40) and the current results support other reports in which the presence of NO was demonstrated in the immune system (33,41).

It has been demonstrated that the expression of NOS and production of NO are characteristic of cells involved in immune responses (33,36,42). Although NO is less active in cells from normal mice (43), a spleen cell subpopulation produces enough NO during an in vitro immune response to completely prevent multiplication of T cells (44,45). Similarly, previous studies have demonstrated that a wide range of potential immunomodulatory functions may be expected for NO in the thymus, including the following: Induction of tolerance, restriction of major histocompatibility complex, lymphocyte trafficking and regulation of thymic endocrine output (33,36,37,42). Furthermore, if there are effects or changes in the cells due to BetA treatment, it is assumed that NO may be produced to perform its regulatory roles in the cells of these immune organs.

Betulin and BetA trigger and modify cytokine production in human whole blood cell cultures (46). To support this hypothesis, previous studies have reported that BetA augments mouse immune function, including cellular and humoral immunity, and activity of phagocytic macrophages (39,47). BetA was identified as a modulatory agent of cytokine production by T helper cells (Th1/Th2) and other immune cells in animals. Consistently, the results of numerous studies indicated that BetA may be useful for modulation of the immune system (40,48–51). Furthermore, various bioactive materials derived from other plants exhibit immunomodulatory abilities (52–55).

In addition, NO is recognized to act as a vasodilator following its release from endothelial cells (56–58), including BetA-treated endothelial cells (59–62). This function is mediated by NO inhibitory action on vascular smooth muscles. However, Moncada et al (25) and other studies (63,64) have demonstrated that NO-mediated vasodilation occurs without endothelial cells present, where the NO-positive nitrergic nerves may act directly on smooth muscle cells, leading to vasodilation. Such control by neuronal NO has also been demonstrated in the peripheral nervous system (65,66).

The innervation of NO-positive perivascular nerves has also been demonstrated in many types of vascular tissue (67–69). The distribution of supply of nerves in the thymus are not entirely known; however, previous studies focused on the neural structures contained within the thymus (70,71). The activity of NADPH-d was demonstrated in many parts of the nervous system in mammals (72–74). The present results are consistent with previous findings that NADPH-d-labelled cells are present in the rat thymus (28,30,75). Although the current study observed NADPH-d-stained nerve fibers in the perivascular area, no NADPH-d neuronal cell body-like structures were observed in either the thymus or the spleen. The moderate distribution of NO-containing nerves travelling along blood vessels may reflect a particularly significant role that neuronal NO may perform in controlling blood flow through the thymus and spleen. The fact that NO-positive nerves and the vascular endothelium may produce NO to influence blood flow has been described in the nervous system (74), pancreas (76), thyroid (27,29) and various other tissues. This observation indicates that NO participates in neurotransmission in the thymus and spleen. It is important to note that in addition to blood vessels, NO may regulate the secretory activity of immune cells by its generation in these cells (77). Thus, BetA may present a promising biological response modifier and may reinforce the immune response of a host.

In conclusion, the current study demonstrates that BetA treatment induces the expression of NADPH-d activity in the thymus and spleen without causing any significant changes to the morphology of the organs. These findings are of direct clinical relevance and may contribute to the progression of drug discovery. To the best of our knowledge, this is the most significant study describing BetA-induced, NADPH-d-mediated NO signaling, which may be the mechanism underlying BetA-elicited immunomodulation in these organs.

 Acknowledgements

The present study was partly supported by an internal research grant (grant no. 1437-0195) obtained from the Deanship of Scientific Research University of Tabuk (Tabuk, Saudi Arabia).

 References GeethaSSinghVRamMSIlavazhaganGBanerjeePKSawhneyRCImmunomodulatory effects of seabuckthorn (Hippophae rhamnoides L.) against chromium (VI) induced immunosuppressionMol Cell Biochem278101109200510.1007/s11010-005-7095-916180095 AravindaramKYangNSAnti-inflammatory plant natural products for cancer therapyPlanta Med7611031117201010.1055/s-0030-124985920432202 WinklerCWirleitnerBSchroecksnadelKSchennachHMurEFuchsDIn vitro effects of two extracts and two pure alkaloid preparations of Uncaria tomentosa on peripheral blood mononuclear cellsPlanta Med70205210200410.1055/s-2004-81553615114496 PatwardhanBGautamMBotanical immunodrugs: Scope and opportunitiesDrug Discov Today10495502200510.1016/S1359-6446(04)03357-415809195 SreeshaTIn-vitro study of cytotoxicity activity of flavonoid fraction from the petals of Cassia sennaInt J Ethnomed Pharmacol Res152552013 NagarathnaPKMReenaKSriramReddyJohnsonWReview on immunomodulation and immunomodulatory activity of some herbal plantsInt J Pharm Sci Rev Res222232302013 IbrahimJWaqasASyed NasirABPlant-derived immunomodulators: An insight on their preclinical evaluation and clinical trialsFront Plant Sci66552015263796834548092 SchepetkinIAQuinnMTBotanical polysaccharides: Macrophage immunomodulation and therapeutic potentialInt Immunopharmacol6317333200610.1016/j.intimp.2005.10.00516428067 EiznhamerDAXuZQBetulinic acid: A promising anticancer candidateIDrugs7359373200415057642 HigaMNohaNYokaryoHOgiharaKYogiSThree new naphthoquinone derivatives from Diospyros maritima BlumeChem Pharm Bull (Tokyo)50590593200210.1248/cpb.50.59012036010 HansonJRPentacyclic triterpenes as promising agents in cancerSalvadorJARNova Science Publishers, IncNew York, NY1912010 SantosRCSalvadorJAMarínSCascanteMMoreiraJNDinisTCSynthesis and structure-activity relationship study of novel cytotoxic carbamate and N-acylheterocyclic bearing derivatives of betulin and betulinic acidBioorg Med Chem1843854396201010.1016/j.bmc.2010.04.08520494586 ZhangDMXuHGWangLLiYJSunPHWuXMWangGJChenWMYeWCBetulinic acid and its derivatives as potential antitumor agentsMed Res Rev3511271155201510.1002/med.2135326032847 Ali-SeyedMJantanIVijayaraghavanKBukhariSNBetulinic acid: Recent advances in chemical modifications, effective delivery, and molecular mechanisms of a promising anticancer therapyChem Biol Drug Des87517536201610.1111/cbdd.1268226535952 AlakurttiSMäkeläTKoskimiesSYli-KauhaluomaJPharmacological properties of the ubiquitous natural product betulinEur J Pharm Sci29113200610.1016/j.ejps.2006.04.00616716572 CsukRBetulinic acid and its derivatives: A patent review (2008–2013)Expert Opin Ther Pat24913923201410.1517/13543776.2014.92744124909232 ZucoVSupinoRRighettiSCClerisLMarchesiEGambacorti-PasseriniCFormelliFSelective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cellsCancer Lett1751725200210.1016/S0304-3835(01)00718-211734332 ThurnherDTurhaniDPelzmannMWannemacherBKnererBFormanekMWacheckVSelzerEBetulinic acid: A new cytotoxic compound against malignant head and neck cancer cellsHead Neck25732740200310.1002/hed.1023112953308 MukherjeeRKumarVSrivastavaSKAgarwalSKBurmanACBetulinic acid derivatives as anticancer agents: Structure activity relationshipAnticancer Agents Med Chem6271279200610.2174/18715200677693084616712455 GalgonTWohlrabWDrägerBBetulinic acid induces apoptosis in skin cancer cells and differentiation in normal human keratinocytesExp Dermatol14736743200510.1111/j.1600-0625.2005.00352.x16176281 SelzerEPimentelEWacheckVSchlegelWPehambergerHJansenBKodymREffects of betulinic acid alone and in combination with irradiation in human melanoma cellsJ Invest Dermatol114935940200010.1046/j.1523-1747.2000.00972.x10771474 PeriasamyGTeketelewGGebrelibanosMSintayehuBGebrehiwotMKarimAGeremedhinGBetulinic acid and its derivatives as anti-cancer agent: A reviewArch Appl Sci Res647582014 MullauerFBKesslerJHMedemaJPBetulinic acid, a natural compound with potent anticancer effectsAnticancer Drugs21215227201010.1097/CAD.0b013e3283357c6220075711 HeissEHKramerMPAtanasovAGBeresHSchachnerDDirschVMGlycolytic switch in response to betulinic acid in non-cancer cellsPLoS One9e115683201410.1371/journal.pone.0115683255317804274109 MoncadaSPalmerRMHiggsANitric oxide: Physiology, pathophysiology and pharmacologyPharmacol Rev4310914219911852778 KnowlesRGMoncadaSNitric oxide synthase in mammalsBiochemical J298249258199410.1042/bj2980249 SyedMALeongSKChanASLocalization of NADPH-diaphorase reactivity in the chick and mouse thyroid glandThyroid4475478199410.1089/thy.1994.4.4757536060 GulatiPLeongSKChanASOntogeny of NADPH-d expression in the thymic microenvironment of the chick embryoCell Tissue Res294335343199810.1007/s0044100511839799449 AkbariZRohaniMHBehzadiGNADPH-d/NOS reactivity in the lumbar dorsal horn of congenitally hypothyroid pups before and after formalin pain inductionInt J Dev Neurosci27779787200910.1016/j.ijdevneu.2009.08.01219720128 FörstermannUSessaWCNitric oxide synthases: Regulation and functionEur Heart J33829837837a-837d201210.1093/eurheartj/ehr30421890489 AndronowskaAChruścielMExpression and cellular distribution of NADPH-diaphorase and nitric oxide synthases in the porcine uterus during early pregnancyFolia Histochem Cytobiol45375380200718165177 AliSMChanASLeongSKLocalization of nitrergic neuronal and non-neuronal cells in the ultimobranchial glands of the chickenAnat Embryol (Berl)193161168199610.1007/BF002147068742056 DorkoFŠpakovskáTLovasováKPatlevičPKluchováDNADPH-d activity in rat thymus after the application of retinoid acidEur J Histochem56e7201210.4081/ejh.2012.e7224728953352136 HopeBTMichaelGJKniggeKMVincentSRNeuronal NADPH diaphorase is a nitric oxide synthaseProc Natl Acad Sci USA8828112814199110.1073/pnas.88.7.2811170717351329 SteinigerBSHuman spleen microanatomy: Why mice do not sufficeImmunology145334346201510.1111/imm.12469258270194479533 DankoJOndrasovicMSvickýEJencaAPospiesznyNOndrasovicováOHistochemical study of innervation and NADPH-D activity of the thymusAnat Histol Embryol32233235200310.1046/j.1439-0264.2003.00470.x12919075 SvickýEOndraovicMDankoJOndrasovicováOJencaAPospiesznyNToropilaMLocalisation of NADPH-diaphorase-positive structures in the thymus of the rat, mouse and rabbitFolia Morphol (Warsz)62167170200314507040 JacobsATIgnarroLJLipopolysaccharide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW 264.7 macrophagesJ Biol Chem2764795047957200110.1074/jbc.M10663920011602590 YiJEObminska-MrukowiczBYuanLYYuanHImmunomodulatory effects of betulinic acid from the bark of white birch on miceJ Vet Sci11305313201010.4142/jvs.2010.11.4.305211130992998741 JineYLisMSzczypkaMObmińska-MrukowiczBInfluence of betulinic acid on lymphocyte subsets and humoral immune response in micePol J Vet Sci15305313201222844709 HibbsJBJrInfection and nitric oxideJ Infect Dis185Suppl 1S9S17200210.1086/33800511865435 IbizaSSerradorJMThe role of nitric oxide in the regulation of adaptive immune responsesImmunología271031172008 FilepJGFöldes-FilepERousseauASiroisPFournierAVascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious ratBr J Pharmacol11012131221199310.1111/j.1476-5381.1993.tb13944.x82988112175793 UmeshappaCSSinghKPNanjundappaRHChannappanavarRMaanSMaanNSBluetongue virus-23 stimulates inducible nitric oxide synthase expression and nitric oxide production in mononuclear cells of blood and/or regional lymphoid organsVet Res Commun36245250201210.1007/s11259-012-9538-623007876 DarwicheSSPfeiferRMenzelCRuanXHoffmanMCaiCChanthaphavongRSLoughranPPittBRHoffmanRInducible nitric oxide synthase contributes to immune dysfunction following traumaShock38499507201210.1097/SHK.0b013e31826c5afe230421893475737 ZdzisińskaBRzeskiWPaduchRSzuster-CiesielskaAKaczorJWejkszaKKandefer-SzerszeńMDifferential effect of betulin and betulinic acid on cytokine production in human whole blood cell culturesPol J Pharmacol55235238200312926552 ChenSBaiYLiZJiaKJinYHeBQiuWWDuCSiwkoSChenHA betulinic acid derivative SH479 inhibits collagen-induced arthritis by modulating T cell differentiation and cytokine balanceBiochem Pharmacol1266978201710.1016/j.bcp.2016.12.00627965071 SultanaNSaifyZSNaturally occurring and synthetic agents as potential anti-inflammatory and immunomodulantsAntiinflamm Antiallergy Agents Med Chem11319201210.2174/18715231280347626422934748 WangPLiQLiKZhangXHanZWangJGaoDLiJBetulinic acid exerts immunoregulation and anti-tumor effect on cervical carcinoma (U14) tumor-bearing micePharmazie67733739201222957441 DashSKChattopadhyaySTripathySDashSSDasBMandalDMahapatraSKBagBGRoySSelf-assembled betulinic acid augments immunomodulatory activity associates with IgG responseBiomed Pharmacother75205217201510.1016/j.biopha.2015.07.03326256937 YiJZhuRWuJWuJXiaWZhuLJiangWXiangSTanZIn vivo protective effect of betulinic acid on dexamethasone induced thymocyte apoptosis by reducing oxidative stressPharmacol Rep6895100201610.1016/j.pharep.2015.07.00326721359 KovalenkoLPBalakshinVVPresnovaGAChistyakovANShipaevaEVAlekseevaSVDurnevADImmunotoxicity and allergenic properties of betulin-containing birch bark dry extractPharm Chem J411719200710.1007/s11094-007-0005-6 NaithaniRHumaLCMoriartyRMMcCormickDLMehtaRGComprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trialsCurr Med Chem1510441071200810.2174/09298670878422140318473802 PaszkiewiczMBudzyńskaARóżalskaBSadowskaBThe immunomodulatory role of plant polyphenolsPostepy Hig Med Dosw (Online)666376362012 (In Polish)10.5604/17322693.100990823001205 MathewNSNegiPSTraditional uses, phytochemistry and pharmacology of wild Banana (Musa acuminata Colla): A reviewJ Ethnopharmacol196124140201710.1016/j.jep.2016.12.00927988402 SchmidtABilgasemSLorkowskiSVischerPVölkerWBreithardtGSiegelGBuddeckeEExogenous nitric oxide regulates activity and synthesis of vascular endothelial nitric oxide synthaseEur J Clin Invest38476485200810.1111/j.1365-2362.2008.01967.x18578689 SonYLeeJHCheongYKJungHCJeongSOParkSHPaeHOPiceatannol, a natural hydroxylated analog of resveratrol, promotes nitric oxide release through phosphorylation of endothelial nitric oxide synthase in human endothelial cellsEur Rev Med Pharmacol Sci1931253132201526367737 TilleryLCEppersonTAEguchiSMotleyEDDifferential regulation of endothelial nitric oxide synthase phosphorylation by protease-activated receptors in adult human endothelial cellsExp Biol Med (Maywood)241569580201610.1177/1535370215622584267290424950326 Steinkamp-FenskeKBollingerLXuHYaoYHorkeSFörstermannULiHReciprocal regulation of endothelial nitric-oxide synthase and NADPH oxidase by betulinic acid in human endothelial cellsJ Pharmacol Exp Ther322836842200710.1124/jpet.107.12335617496167 QianLBFuJYCaiXXiaMLBetulinic acid inhibits superoxide anion-mediated impairment of endothelium-dependent relaxation in rat aortasInd J Pharmacol44588592201210.4103/0253-7613.100382 HohmannNXiaNSteinkamp-FenskeKFörstermannULiHEstrogen receptor signaling and the PI3K/Akt pathway are involved in betulinic acid-induced eNOS activationMolecules21E973201610.3390/molecules2108097327463705 JinSWChoiCYHwangYPKimHGKimSJChungYCLeeKJJeongTCJeongHGBetulinic acid increases eNOS phosphorylation and no synthesis via the calcium-signaling pathwayJ Agric Food Chem64785791201610.1021/acs.jafc.5b0541626750873 ChenMFHuangYCLongCYangHILeeHCChenPYHofferBJLeeTJBimodal effects of fluoxetine on cerebral nitrergic neurogenic vasodilation in porcine large cerebral arteriesNeuropharmacology6216511658201210.1016/j.neuropharm.2011.11.01122155207 LiesBBeckKKepplerJSaurDGronebergDFriebeANitrergic signalling via interstitial cells of Cajal regulates motor activity in murine colonJ Physiol59345894601201510.1113/JP270511262270634606533 WenischSArnholdSNADPH-diaphorase activity and NO synthase expression in the olfactory epithelium of the bovineAnat Histol Embryol39201206201010.1111/j.1439-0264.2010.00996.x20331592 ŞelaruMRusuMCJianuAMExpression of nNOS in the human larynxAnat Sci Int90327330201510.1007/s12565-015-0272-325656267 KnippingSHolzhausenHJBerghausABlochingMRiedererAUltrastructural detection of nitric oxide in human nasal mucosaOtolaryngol Head Neck Surg132620625200510.1016/j.otohns.2005.01.02515806057 KoyamaTHatanakaYJinXYokomizoAFujiwaraHGodaMHobaraNZamamiYKitamuraYKawasakiHAltered function of nitrergic nerves inhibiting sympathetic neurotransmission in mesenteric vascular beds of renovascular hypertensive ratsHypertens Res33485491201010.1038/hr.2010.4820379183 ShimadaSTodokiKOmoriYToyamaTMatsuoMWada-TakahashiSTakahashiSSLeeMCContribution of nitrergic nerve in canine gingival reactive hyperemiaJ Clin Biochem Nutr5698104201510.3164/jcbn.14-71257595144345180 MigniniFSabbatiniMD'AndreaVCavallottiCIntrinsic innervation and dopaminergic markers after experimental denervation in rat thymusEur J Histochem54e17201010.4081/ejh.2010.e17205583393167301 DorkoFDankoJFlešárováSBorošESobekováAEffect of pesticide bendiocar-bamate on distribution of acetylcholine- and butyrylcholine-positive nerves in rabbit's thymusEur J Histochem55e37201110.4081/ejh.2011.e37222974433284239 LiuCYangYHuXLiJMZhangXMCaiYLiZYanXXOntogenesis of NADPH-diaphorase positive neurons in guinea pig neocortexFront Neuroanat911201510.3389/fnana.2015.00011257629004329812 JungJNaCHuhYAlterations in nitric oxide synthase in the aged CNSOxid Med Cell Longev2012718976201210.1155/2012/718976228299603399597 CossenzaMSocodatoRPortugalCCDomithICGladulichLFEncarnaçãoTGCalazaKCMendonçaHRCampello-CostaPPaes-de-CarvalhoRNitric oxide in the nervous system: Biochemical, developmental, and neurobiological aspectsVitam Horm9679125201410.1016/B978-0-12-800254-4.00005-225189385 DowningJEMultiple nitric oxide synthase systems in adult rat thymus revealed using NADPH diaphorase histochemistryImmunology82659664199475306861414902 VillanuevaCGiuliviCSubcellular and cellular locations of nitric-oxide synthase isoforms as determinants of health and diseaseFree Radic Biol Med49307316201010.1016/j.freeradbiomed.2010.04.004203885372900489 BogdanCNitric oxide synthase in innate and adaptive immunity: An updateTrends Immunol36161178201510.1016/j.it.2015.01.00325687683

Structure of triterpenoid alcohol betulin and the corresponding carboxylic acid betulinic acid.

Representative photomicrographs demonstrating thymus sections of the (A-C) VC (dimethyl sulfoxide), (D-F) positive (GTN) and (G-I) BetA-treated groups on days 4, 8 and 12 after treatment. Inset (IS) is representative of the area in the figure outlined in black. Black arrows identify the NADPH-d-stained blood vessels (BV), the red arrow points the perivascular nerve fibres and blue arrow demonstrates the NADPH-d positive cells in the cortex (denoted by the letter C) and medulla (denoted by the letter M). The letter ‘S’ indicates the interlobular septum. Scale bar, 100 µm. (J) The intensity (OD) of the NADPH-d staining was quantified using Olympus Soft Imaging cellSens software version 1.6. Data are expressed as means ± standard deviation of mice (n=6 per group) **P<0.001 vs. the VC group, #P<0.001 vs. the GTN group. †P<0.01 vs. the VC group. GTN, goniothalamin; BetA, betulinic acid; NADPH-d, nicotinamide adenine dinucleotide phosphate diaphorase; VC, vehicle control; OD, optical density.

Representative photomicrographs demonstrating spleen sections the (A-C) VC (dimethyl sulfoxide), (D-F) positive (GTN) and (G-I) BetA-treated groups on days 4, 8 and 12 after treatment. Inset (IS) is representative of the area in the figure outlined in black. Black arrows identify the NADPH-d-stained blood vessels (BV), the red arrow points the perivascular nerve fibres and blue arrow demonstrates the NADPH-d positive cells in the red pulp (RP) region. ‘WP’ indicates the white pulp region. Scale bar, 100 µm. (J) The intensity (OD) of the NADPH-d staining was quantified using Olympus Soft Imaging cellSens software version 1.6. Data are expressed as means ± standard deviation of mice (n=6 per group) **P<0.001 vs. the VC group, #P<0.001 vs. the GTN group, †P<0.01 vs. the VC group. GTN, goniothalamin; BetA, betulinic acid; NADPH-d, nicotinamide adenine dinucleotide phosphate diaphorase; VC, vehicle control; OD, optical density.